Medicus Services s.r.o.
- Address
- lock Available on a paid plan
Medicus Services s.r.o. - Cardiovascular and Metabolic Research Center
Medicus Services s.r.o. is a specialized clinical research center with extensive expertise in cardiovascular disease prevention and lipid metabolism disorders. The center demonstrates particular strength in conducting complex Phase 3 trials evaluating novel therapeutics for patients at high cardiovascular risk, including those with atherosclerotic cardiovascular disease (ASCVD) and various dyslipidemias.
- Advanced lipid-modifying therapies and cholesterol management, including studies of obicetrapib, olezarsen, inclisiran, and AZD0780 for dyslipidemia and severe hypertriglyceridemia
- Stroke prevention in atrial fibrillation patients, with focus on novel anticoagulation strategies including abelacimab and milvexian
- Primary and secondary prevention of major adverse cardiovascular events (MACE) in high-risk populations
The center's research portfolio emphasizes cardiovascular outcomes trials designed to demonstrate reduction in clinically meaningful endpoints such as cardiovascular death, myocardial infarction, and ischemic stroke. With experience in both placebo-controlled and active-controlled study designs, Medicus Services s.r.o. specializes in recruiting and managing complex patient populations, including those deemed unsuitable for standard therapies and patients requiring intensive lipid management to prevent atherosclerotic disease progression.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB6trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medicus Services s.r.o.
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Baxdrostat | 3 | Unknown | 2024-03-08 | 2025-05-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.